Back to Analysis

AbbVie

ABBV

Healthcare

Biopharmaceutical company focused on immunology, oncology, and aesthetics. Former maker of Humira.

View forensic report

2 articles about AbbVie

Capital AllocationABBV

The Chart That Explains AbbVie's Post-Humira Capital Allocation

AbbVie's dividend yield of 3.1% and aggressive acquisition strategy tell a story the income statement alone can't — management is betting the Humira cliff was already priced in and is deploying capital for the next growth cycle.

Apr 13, 2026
Deep DivesABBV

Inside AbbVie's Post-Humira Playbook: Pipeline Promise Meets Margin Reality

Revenue has recovered past the Humira patent cliff to $61.2 billion, but net income stuck at $4.2 billion exposes the gap between top-line replacement and bottom-line recovery.

Apr 12, 2026